List of Excipients in Branded Drug AMINOCAPROIC ACID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	AMINOCAPROIC ACID	aminocaproic acid	0054-1110	CROSPOVIDONE
Hikma Pharmaceuticals USA Inc	AMINOCAPROIC ACID	aminocaproic acid	0054-1110	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	AMINOCAPROIC ACID	aminocaproic acid	0054-1110	POVIDONE K30
Hikma Pharmaceuticals USA Inc	AMINOCAPROIC ACID	aminocaproic acid	0054-1110	STEARIC ACID

Generic Drugs Containing AMINOCAPROIC ACID

Company	Ingredient	NDC	Excipient
Henry Schein Inc	aminocaproic acid	0404-9812	HYDROCHLORIC ACID
Henry Schein Inc	aminocaproic acid	0404-9812	WATER
Hospira, Inc.	aminocaproic acid	0409-4346	HYDROCHLORIC ACID
Hospira, Inc.	aminocaproic acid	0409-4346	WATER

What are the Most Frequently-Used Excipients in AMINOCAPROIC ACID?

# Of NDCs	Excipient
1	ACESULFAME
1	ACETIC ACID
1	AMMONIUM GLYCYRRHIZATE
14	ANHYDROUS CITRIC ACID

Excipient Strategy and Commercial Opportunities for Aminocaproic Acid

Last updated: February 27, 2026

What is the Role of Excipients in Aminocaproic Acid Formulations?

Aminocaproic acid (ACA) is an antifibrinolytic agent used to control bleeding in surgical and trauma settings. The formulation of ACA relies heavily on excipients to ensure stability, bioavailability, and patient tolerability.

• Current formulations include injectable solutions, oral tablets, and capsules.
• Injectable formulations require isotonic solutions, buffers, and stabilizers.
• Oral forms often contain fillers, binders, disintegrants, and lubricants for tablet integrity and ease of swallowing.

Excipients influence drug stability, shelf life, and absorption. For ACA, excipient choice impacts:

• pH buffering to maintain drug stability
• Preservation against microbial contamination
• Ease of administration and patient compliance

What Are the Key Excipient Components in Existing Formulations?

Injectable Formulations

• Buffer agents (e.g., sodium chloride, sodium bicarbonate) to maintain pH
• Preservatives (e.g., benzyl alcohol) in multi-dose formulations
• Stabilizers (e.g., mannitol) to prevent degradation during storage
• Solutions require isotonic agents to minimize vascular irritation

Oral Formulations

• Fillers (e.g., lactose, microcrystalline cellulose)
• Binders (e.g., povidone, hydroxypropyl methylcellulose)
• Disintegrants (e.g., sodium starch glycolate)
• Lubricants (e.g., magnesium stearate)
• Coatings in tablets to mask taste or protect from environmental degradation

How Can Excipient Strategies Drive Commercial Opportunities?

Enhancing Formulation Stability and Shelf Life

• Developing novel stabilizers or buffers that extend shelf life, reducing logistical costs
• Using excipients that improve thermal stability, enabling storage and transport in diverse environments

Improving Bioavailability and Patient Tolerability

• Employing excipients that facilitate faster dissolution or absorption
• Incorporating taste-masking agents in oral forms to increase patient compliance

Expanding Patent and Market Life

• Innovating with excipients to create new formulations (e.g., sustained-release, transdermal)
• Patenting novel excipient combinations as secondary patents

Cost Reduction and Supply Chain Optimization

• Transitioning to scalable, economical excipients
• Developing excipient blends tailored for large-volume manufacturing

Developing Novel Delivery Platforms

• Liposomal, nanoparticle, or sustained-release implants that rely on specific excipient matrixes
• License or partner with excipient suppliers to access cutting-edge technologies

What Are the Regulatory Considerations?

• Excipients must be compatible with active ingredients and meet safety standards.
• US FDA and EMA specify acceptable excipient lists with concentration limits.
• Novel excipients require extensive safety data and may delay approval timelines.
• Patent strategies should account for regulatory pathways for excipient innovations.

What Are the Market Trends and Opportunities?

• The global antifibrinolytic market, projected to reach USD 1.5 billion by 2027 [1], presents opportunities for innovative formulations.
• Increasing demand for pediatric and geriatric formulations encourages development of excipient profiles tailored for sensitive populations.
• Growing interest in biosimilar and generic versions emphasizes excipient optimization to differentiate products.

Competitive Landscape

Player	Focus Area	Key Innovation
Baxter	Injectable formulations	Stabilizer technology
Pfizer	Oral tablets	Taste-masking excipients
Merck KGaA	Liposomal delivery systems	Novel excipient matrices
Recipharm	Contract manufacturing	Custom excipient blends

Summary of Opportunities and Challenges

Opportunity	Challenge
Creating more stable, long-shelf-life formulations	Regulatory approval for new excipients
Developing patient-friendly, tolerable forms	Cost implications of novel excipients
Innovating delivery platforms	Patent and IP considerations

Key Takeaways

• Excipients are critical for stabilizing, delivering, and enhancing the patient experience of aminocaproic acid formulations.
• Strategic excipient choices can extend product shelf life, improve bioavailability, and differentiate products in competitive markets.
• Innovation in excipient technology offers pathways to extend patent protection, reduce costs, and expand indications.
• Regulatory compliance remains a key hurdle in introducing novel excipient combinations.
• The expanding antifibrinolytic market emphasizes the importance of excipient optimization for future growth.

FAQs

1. What are the main excipients used in aminocaproic acid injectables?
Buffer agents (e.g., sodium bicarbonate), stabilizers (e.g., mannitol), preservatives (e.g., benzyl alcohol), and isotonic agents (e.g., sodium chloride).

2. Are there patented excipient combinations for aminocaproic acid?
While specific patents exist on formulations, novel excipient combinations or delivery methods may offer new patent opportunities.

3. What impact do excipients have on the bioavailability of oral aminocaproic acid?
Excipients like disintegrants and binders influence dissolution and absorption rates, affecting bioavailability.

4. How does excipient choice affect regulatory approval?
Acceptable excipients must meet safety standards; novel excipients require extensive testing and approval, potentially delaying product launch.

5. What trends are shaping excipient development in antifibrinolytic drugs?
Increased focus on stability, patient tolerability, cost-efficiency, and innovative delivery systems drive excipient research and development.

---

References

[1] MarketsandMarkets. (2021). Antifibrinolytic Drugs Market by Product (Injectable, Oral), Application (Cardiac Surgery, Orthopedic Surgery), and Region.